Premium
APLASTIC ANEMIA DURING ETHOSUXIMIDE MEDICATION
Author(s) -
SEIP M.
Publication year - 1983
Publication title -
acta pædiatrica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.772
H-Index - 115
eISSN - 1651-2227
pISSN - 0803-5253
DOI - 10.1111/j.1651-2227.1983.tb09845.x
Subject(s) - medicine , ethosuximide , aplastic anemia , regimen , methylprednisolone , surgery , bolus (digestion) , pancytopenia , anemia , pediatrics , epilepsy , phenytoin , bone marrow , psychiatry
. A girl, born in 1975, developed severe aplastic anemia in November 1982 while on ethosuximide monotherapy for petit mal epilepsy, about 3 months after starting the ethosuximide medication. She was treated with bolus‐methylprednisolone as described by Bacigalup et al. (13), transfusions and antibiotics. During the third week on this regimen slight improvements in granulocyte and reticulocyte counts were demonstrated, and after approximately 6 weeks she was in stable condition without further need of transfusions. Blood status should be checked regularly during ethosuximide therapy, particularly during the first 6 months.